Sera Prognostics, Inc. (SERA) Stock Price & Analysis
Sera Prognostics, Inc. (SERA) rose 1.43% to USD 2.13 as of June 10, 2026 at 05:14 UTC, according to Nexqual real-time market data.
SERA last closed at USD 2.1; the session ranged USD 1.96–2.24 on volume of 57,551 shares. Market capitalization is $83.41M, with a 52-week range of USD 1.43–4.09 (NGM). Source: Nexqual, June 10, 2026 at 05:14 UTC.
Key Statistics (as of June 10, 2026 at 05:14 UTC)
| Price | USD 2.13 |
|---|---|
| Change | ▲ 1.43% (up) |
| Previous Close | USD 2.1 |
| Open | USD 2.13 |
| Day Range | USD 1.96 – 2.24 |
| 52-Week Range | USD 1.43 – 4.09 |
| Volume | 57,551 shares |
| Market Cap | $83.41M |
| Exchange | NGM |
Technical Analysis (SERA)
Nexqual's technical model rates SERA "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.64 (neutral) |
| vs SMA50 | Above (USD 2.02) |
| MACD | 0.06 (positive) |
Analyst Ratings (SERA)
Wall Street analysts rate SERA "Strong Buy" based on 2 analysts, with a mean price target of USD 5.5 (range USD 5–6), per Nexqual as of June 10, 2026 at 05:14 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.5 |
| High Target | USD 6 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SERA)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.16 |
| Revenue Estimate | $50,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.17 vs est -0.17 ▲ beat |
| 2025-12-31 | USD -0.16 vs est -0.19 ▲ beat |
| 2025-09-30 | USD -0.16 vs est -0.21 ▲ beat |
| 2025-06-30 | USD -0.16 vs est -0.24 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:14 UTC.
Financials & Fundamentals (SERA)
| Total Revenue | $57,000 |
|---|---|
| Revenue Growth (YoY) | -63.20% |
| Gross Margin | -191.23% |
| Operating Margin | -66857.14% |
| Profit Margin | +0.00% |
| ROE | -39.58% |
| Debt / Equity | 3.71 |
| Current Ratio | 2.12 |
| Total Cash | $47.40M |
| Total Debt | $2.50M |
| Free Cash Flow | $-18.90M |
Source: Nexqual, June 10, 2026 at 05:14 UTC.
Financial Health Score (SERA)
Nexqual rates Sera Prognostics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:14 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $47M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$19M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -21.6% |
Ownership (SERA)
| Insider Ownership | +11.58% |
|---|---|
| Institutional Ownership | +63.14% |
| Shares Outstanding | 38.19M |
| Float | 27.60M |
| Short % of Float | +0.96% |
Source: Nexqual, June 10, 2026 at 05:14 UTC.
Leadership (SERA)
Sera Prognostics, Inc. is led by Zhenya Lindgardt (age 51), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:14 UTC.
| President, CEO & Director | Zhenya Lindgardt (age 51) |
|---|---|
| Chief Scientific Officer | John J. Boniface (age 63) |
| Executive Director | Gregory C. Critchfield M.D., M.S. (age 72) |
| Chief Financial Officer | Austin Aerts (age 38) |
Major Backers & Investors (SERA)
Notable institutional backers of Sera Prognostics, Inc. include Baker Bros. Advisors, LP, Whetstone Capital Advisors, LLC, Aberdeen Group plc, according to Nexqual as of June 10, 2026 at 05:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 14.4% |
| Whetstone Capital Advisors, LLC | 8.66% |
| Aberdeen Group plc | 6.68% |
| abrdn Healthcare Investors | 6.68% |
| Psp Research LLC | 6.28% |
| Vivo Capital, LLC | 4.32% |
| CAPTRUST Financial Advisors | 1.41% |
| Sanders Morris Harris LLC | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.27% |
| Geode Capital | 0.95% |
Source: Nexqual, June 10, 2026 at 05:14 UTC.
From Sera Prognostics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
- The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
- It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| NEXI | NexImmune, Inc. | USD 0 | ▲ 0% |
| TCRX | TScan Therapeutics, Inc. | USD 0.97 | ▼ 1.68% |
| SGHT | Sight Sciences, Inc. | USD 4.85 | ▲ 8.99% |
| SNTG | Sentage Holdings Inc. | USD 2.21 | ▼ 7.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:14 UTC. This page is informational and not investment advice.